Mediterranean diet, physical activity and subcutaneous advanced glycation end-products’ accumulation: a cross-sectional analysis in the ILERVAS project

2019 ◽  
Vol 59 (3) ◽  
pp. 1233-1242 ◽  
Author(s):  
Enric Sánchez ◽  
◽  
Àngels Betriu ◽  
Jordi Salas-Salvadó ◽  
Reinald Pamplona ◽  
...  
Keyword(s):  
Physical Activity ◽  
Mediterranean Diet ◽  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Cross Sectional Analysis ◽  
Glycation End Products ◽  
End Products ◽  
Sectional Analysis

scholarly journals Advanced Glycation End Products Levels and Carotid Intima Media Thickness in Patients With Rheumatoid Arthritis

2019 ◽  
Vol 10 (2) ◽  
pp. 58
Author(s):  
Ines KNANI ◽  
Hassan BOUZIDI ◽  
Albert LECUBE ◽  
Jawhar GHARBI ◽  
Mohsen KERKENI
Keyword(s):  
Rheumatoid Arthritis ◽  
Advanced Glycation End Products ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Cross Sectional Study ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Media Thickness ◽  
Glycation End Products ◽  
End Products

Introduction: No data regarding the relationship of carotid intima media thickness (IMT) and serum advanced glycation end products (AGEs) levels in patients with rheumatoid arthritis (RA). The aim of this study is to evaluate the association between IMT and serum pentosidine, CML and MGO levels in patients with longstanding RA.Methods: In a cross-sectional study, 80 consecutive RA patients with longstanding disease were included and compared with 30 age and sex-matched healthy controls. IMT was measured using ultrasonography. AGEs such as pentosidine, Ne-carboxymethyllysine (CML) and methylglyoxal (MGO) as an intermediate of glycation, were determined by ELISA.Results: Serum pentosidine, CML and MGO levels were increased in RA patients vs control subjects (P = 0.001; P < 0.001; P < 0.001 respectively). IMT was increased with disease activity of RA (P = 0.004) and was associated with serum pentosidine (r = 0.460, P < 0.001), serum CML (r = 0.549, P < 0.001) and serum MGO (r = 0.658, P < 0.001). Furthermore, in a multiple stepwise regression analysis CML and MGO were independently associated with IMT (b= 0.333, P = 0.007; b = 0.690, P < 0.001, respectively).Conclusion: serum pentosidine, CML and MGO were increased in RA patients and were significantly related to IMT. Serum CML and MGO were independently associated with IMT.

scholarly journals Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Eva O. Melin ◽  
Jonatan Dereke ◽  
Magnus Hillman
Keyword(s):  
Type 1 Diabetes ◽  
Advanced Glycation End Products ◽  
Inflammatory Responses ◽  
Lipid Lowering ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Lipid Lowering Drugs ◽  
Glycation End Products ◽  
End Products

Abstract Background The receptors for advanced glycation end products (RAGE) are increased in atherosclerotic plaques. Soluble (s)RAGE decreases, whereas the extracellular newly identified receptor for advanced glycation end products (EN-RAGE) increases inflammatory responses mediated by RAGE. The aims were to explore whether sRAGE, EN-RAGE and the EN-RAGE/sRAGE ratio, were associated with the use of lipid-lowering drugs (LLD) and/or antihypertensive drugs (AHD) in patients with type 1 diabetes (T1D). Methods Cross-sectional design. T1D patients were consecutively recruited from one diabetes clinic. Blood samples were collected, supplemented with data from electronic health records. sRAGE and EN-RAGE were analysed by enzyme linked immunosorbent assays. An EN-RAGE/sRAGE ratio was calculated. Adjustments were performed with inflammatory and metabolic variables, s-creatinine, depression, smoking, physical inactivity, medication, and cardiovascular complications. Multiple regression analyses were performed. Results In this study 283 T1D patients (men 56%, 18–59 years) were included. One-hundred and thirty LLD users compared to 153 non-users had lower levels of the EN-RAGE/sRAGE ratio (P = 0.009), and 89 AHD users compared to 194 non-users had lower levels of sRAGE (P = 0.031). The use of LLD (inversely) (B coefficient − 0.158, P = 0.033) and the use of AHD (B coefficient 0.187, P = 0.023) were associated with the EN-RAGE/sRAGE ratio. sRAGE (Lg10) (per unit) (adjusted odds ratio (AOR) = 3.5, 95% CI = 1.4–9.1, P = 0.009), EN-RAGE (Lg10) (per unit) (inversely) (AOR 0.4, 95% CI = 0.2–1.0, P = 0.046), age (P <  0.001), and triglycerides (P <  0.029), were associated with LLD. sRAGE (Lg10) (per unit) (inversely) (AOR = 0.2, 95% CI = 0.1–0.5, P = 0.001), diabetes duration, triglycerides, s-creatinine, and systolic BP (all P values < 0.043), were associated with AHD. Conclusions Higher sRAGE levels and lower EN-RAGE levels were linked to the use of LLD, whereas lower sRAGE levels were linked to the use of AHD. No other variables but the use of LLD and the use of AHD were linked to the EN-RAGE/sRAGE ratio. This may be of major importance as sRAGE is an inhibitor and EN-RAGE is a stimulator of inflammatory processes mediated by RAGE.

scholarly journals Soluble Receptor for Advanced Glycation End Products and Its Correlation with Vascular Damage in Adolescents with Obesity

2019 ◽  
Vol 92 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Reyna Rodríguez-Mortera ◽  
Claudia Luevano-Contreras ◽  
Sergio Solorio-Meza ◽  
Armando Gómez-Ojeda ◽  
Russell Caccavello ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Vascular Damage ◽  
Atherogenic Index ◽  
Stiffness Index ◽  
Model Assessment ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Glycation End Products ◽  
End Products

Objective: The aim of this study was to evaluate soluble receptor for advanced glycation end products (sRAGE) and advanced glycation end products (AGEs) in adolescents with and without obesity (OB) and their correlation with vascular damage. Methods: This is a cross-sectional study with 15–19 years old adolescents: 33 with OB and 33 with normal weight (NW), each group included 17 male and 16 female. Lipid profile, insulin, carboxymethylysine (CML), sRAGE, total AGEs, and dietary AGEs intake (dAGEs) were evaluated. Vascular damage was measured by flow-mediated vasodilation (FMD) and arterial stiffness index (Iβ). Homeostatic model assessment-insulin (HOMA-IR) and atherogenic index (AI) were calculated. Results: The group with OB had higher triglycerides (TG; p < 0.0001), AI (p < 0.001), HOMA-IR (p < 0.0001), dAGEs intake (p < 0.0001), lower CML (p = 0.05), total AGEs (p < 0.01), sRAGE (p < 0.001), and FMD (p < 0.002). In the total group, sRAGE correlated with AI (r = –0.26 p = 0.037); in the NW group, CML correlated with Iβ (r = –0.36; p = 0.037); and in the group of adolescents with OB, sRAGE correlated with FMD (r = –0.37; p = 0.037) and Iβ (r = 0.47; p = 0.006), while CML and total AGEs correlated with AI, p = 0.007 and p < 0.01, respectively). Conclusions: The group of adolescents with OB showed higher cardiometabolic risk as shown by higher TG, AI, HOMA-IR, and lower sRAGE and FMD. sRAGE correlated negatively with FMD and positively with Iβ, so it could be suggested as a biochemical marker of impaired endothelial function.

scholarly journals Dietary Advanced Glycation End-Products (dAGEs) Intake and Bone Health: A Cross-Sectional Analysis in the Rotterdam Study

Nutrients ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2377
Author(s):  
Komal Waqas ◽  
Jinluan Chen ◽  
Bram C. J. van der Eerden ◽  
M. Arfan Ikram ◽  
André G. Uitterlinden ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Bone Health ◽  
Osteoporotic Fractures ◽  
Dietary Quality ◽  
Rotterdam Study ◽  
Advanced Glycation ◽  
Mineral Density ◽  
Cross Sectional ◽  
Glycation End Products ◽  
End Products

Animal studies suggest a role for dietary advanced glycation end-products (dAGEs) in bone health, but human studies on dAGEs in relation to bone are lacking. We aimed to study whether dAGEs intake is associated with the parameters of bone strength namely, bone mineral density (BMD), prevalent vertebral (VFs), and major osteoporotic fractures (MOFs = hip, wrist, proximal humerus, and clinical VFs). 3949 participants (mean age 66.7 ± 10.5 years) were included from a Rotterdam study for whom Carboxymethyllysine (CML—a dietary AGE) was estimated from food frequency questionnaires combined with dAGEs databases. Multivariable linear and logistic regression models were performed adjusting for age, sex, energy intake, dietary quality, physical activity, diabetes, smoking, renal function, and cohort effect and for models on fractures, subsequently for BMD. We observed no association of CML with BMD at both femoral neck (β = −0.006; p = 0.70) and lumbar spine (β = −0.013; p = 0.38). A higher intake of CML was linearly associated with VFs (Odds ratio, OR = 1.16, 95% CI (1.02–1.32) and a similar but non-significant trend with MOFs (OR = 1.12 (0.98–1.27). Additional adjustment for BMD did not change the associations. Our results imply a positive association between dietary intake of CML and VFs independent of BMD. Future studies are needed in order to elucidate whether associations found are causal.

Mediterranean Diet: A Strategy to Reduce Dietary Advanced Glycation End Products Intake

2018 ◽  
Vol 118 (10) ◽  
pp. A135
Author(s):  
B. Turan-Demirci ◽  
K. Isgin-Atici ◽  
S. Sendur ◽  
T. Erbas ◽  
Z. Buyuktuncer
Keyword(s):  
Mediterranean Diet ◽  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products
Sign in / Sign up

Export Citation Format

Share Document